MRTX News and Press, Mirati Therapeutics Inc. From 04/26/23

Journal of Clinical Oncology Publishes Rapid Communication Featuring Updated Clinical Data for Adagrasib as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors PR Newswire Data demonstrates compelling clinical activity, highlights adagrasib potential as monothera...

Mirati Therapeutics® to Report First Quarter 2023 Financial Results and Recent Corporate Updates on May 9, 2023 PR Newswire SAN DIEGO , April 25, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, wil...

2023-04-13 00:30:00 ET Summary In the Russell 1,000, 33 names are up more than 1,000% since April 12th, 2013. Over the same 10-year period, the S&P 500 tracking ETF is up 211%. The obvious next question is: which stocks will be ten baggers over the next ten years? ...

2023-04-09 12:00:00 ET The largest meeting in the world of cancer research is set to kick off this week. The annual meeting of the American Association for Cancer Research (AACR) is a much sought-after event in the healthcare calendar, with many pharma companies scheduled to highlight their...

2023-04-04 22:01:45 ET Summary Baker Brothers’ 13F portfolio value increased from $15.27B to $16.65B this quarter. Replimune Group stake was substantially increased this quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to alm...

Mirati To Present Research at the AACR Annual Congress for Two Potentially First-in-Class Clinical Stage Programs PR Newswire Preclinical data highlights MRTX0902 and MRTX1719 as potentially compelling targeted oncology treatment options SAN DIEGO , April...

2023-03-20 03:43:10 ET Summary Mirati Therapeutics specializes in developing cancer treatments targeting genetic and immunological causes, with Krazati being their first FDA-approved product. Krazati is used to treat adult patients with KRAS G12C-mutated locally advanced or metast...

Mirati Therapeutics to Participate at the Barclays Global Healthcare Conference PR Newswire SAN DIEGO , March 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Barclays Global H...

Mirati Therapeutics, Inc. (MRTX) Q4 2022 Earnings Conference Call February 28, 2023, 04:30 PM ET Company Participants Ryan Asay - VP of Corporate Affairs David Meek - CEO Charles Baum - President, Founder and Head of R&D Laurie Stelzer - CFO James Christens...

Mirati Therapeutics press release ( NASDAQ: MRTX ): Q4 GAAP EPS of -$3.51 beats by $0.16 . Revenue of $0.93M (+210.0% Y/Y) misses by $1.72M . For further details see: Mirati Therapeutics GAAP EPS of -$3.51 beats by $0.16, revenue of $0.93M misses by $1.72M